Suchergebnisse - "Delforge, Michel"

PubPharm (280)

1

Proliferative glomerulonephritis with monoclonal immunoglobulin deposits in the native or posttransplant kidney

enthalten in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association | 2024

von Verbinnen, M. | Sprangers, B. | Abrahams, A. | +9

2

Plain Language Summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma

enthalten in: Future oncology (London, England) | 2024

von Rodriguez-Otero, P. | Ailawadhi, S. | Arnulf, B. | +19

3

Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens : patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial

enthalten in: The Lancet. Haematology | 2024

von Delforge, M. | Patel, K. | Eliason, L. | +15

ErratumIn: Lancet Haematol. 2024 Mar 12;:. - PMID 38490233

4

Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma : Results From the Phase II MajesTEC-1 Study

enthalten in: Clinical lymphoma, myeloma & leukemia | 2024

von Martin, T. | Moreau, P. | Usmani, S. | +20

5

Belantamab mafodotin : an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma

enthalten in: Haematologica | 2024

von Mateos, M. | Weisel, K. | Terpos, E. | +13

6

Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

enthalten in: Advances in therapy | 2024

von Moreau, P. | Mateos, M. | Gonzalez Garcia, M. | +26

7

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

enthalten in: The New England journal of medicine | 2024

von Sonneveld, P. | Dimopoulos, M. | Boccadoro, M. | +141

CommentIn: N Engl J Med. 2024 Apr 18;390(15):1440. - PMID 38631009

8

Comparative Effectiveness of Teclistamab Versus Real-World Physician’s Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

enthalten in: Advances in therapy | 2023

von Moreau, P. | Mateos, M. | Gonzalez Garcia, M. | +26

9

An indirect treatment comparison of efficacy and health-related quality of life following treatment with idecabtagene vicleucel versus belantamab mafodotin in triple-class exposed relapsed/refractory patients with multiple myeloma

enthalten in: Leukemia & lymphoma | 2023

von Rodríguez Otero, P. | Towle, K. | Cope, S. | +11

10

Predictors of Lenalidomide Refractory Relapse Timing With Newly Diagnosed Multiple Myeloma : A FIRST Trial Subanalysis

enthalten in: Clinical lymphoma, myeloma & leukemia | 2023

von Manier, S. | Dimopoulos, M. | Hulin, C. | +7

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[28]